L'Oréal's Episkin buys out SkinEthic - tissue making firm
06 Mar '06
2 min read
Cosmetic group L'Oréal has underlined its commitment to the further development of alternative methods for safety evaluation with the announcement that Episkin, a subsidiary of the group that is dedicated to the development of reconstructed skin, has acquired SkinEthic.
SkinEthic is an important worldwide player in the production and commercialisation of human epidermal and epithelial tissues (including epidermis, dermis, corneal, oral, gingival, oesophageal epithelium, alveolar and vaginal mucosa) for in vitro test applications across many industries.
Cosmetic maker L'Oréal's ultimate goal is to develop a range of approaches and standardised in vitro methods that can be used to test ingredient safety and shared across a number of industry sectors; with the aim of accelerating the elimination of animal testing.
The complimentary nature of Episkin and SkinEthic allows L'Oréal to further advance its commitment to the development of alternative methods for the safety assessment of product ingredients.
Commenting on the acquisition, Jean-François Grollier, Vice-President of Research and Development at L'Oréal said “Providing cutting-edge teams, such as these, with the opportunity to work at the crossroads of science and industry, demonstrates our support for sustainable innovation.”
"The acquisition of SkinEthic allows us to respond to the needs of the entire industry and more specifically in the area of alternative approaches to animal testing – a top priority for L'Oréal”, he continued.
-Ltd..jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Thermore (Far East) Ltd.")
.jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Telangana State Industrial Infrastructure Corporation Limited (TSllC Ltd)")
.jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Taiwan Textile Federation (TTF)")
